Q-Core targets ambulatory pump technology at US & EU markets
This article was originally published in Clinica
Executive Summary
Israeli pump technology specialist Q-Core (Ramat Gan) is targeting the launch of its AP 34-M multi-therapy infusion pump and EF 34-M enteral feeding pump in the US and EU markets this year. The products, based on Q-Core's proprietary electromagnetic flow control (EFC) technology, include software-controlled pump and valve technology and are designed to answer the growing need to reduce capital costs while enhancing patients' quality-of-life by treating them at alternative sites to hospitals.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.